Compare Slide Insurance Holdings Inc. Common Stock (SLDE) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Slide Insurance Holdings Inc. Common Stock vs Sanofi SA — how do they compare? Slide Insurance Holdings Inc. Common Stock trades at $25.59 (market cap $2.98B), while Sanofi SA trades at $40.51 (market cap $94.58B). The key difference: Sanofi SA is far larger — about 31.7× Slide Insurance Holdings Inc. Common Stock's market cap, and Sanofi SA pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Slide Insurance Holdings Inc. Common Stock for 0 Days and Sanofi SA for 94 Days on average.
| SLDE | SNY | |
|---|---|---|
Market Cap | $2.98B | $94.58B |
Volume | 927,183 | 3,988,460 |
Sector | Financials | Health |
52-Week High | $26.48 | $52.34 |
52-Week Low | $14.38 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $1.78B | $113.80B |
Dividend Yield | 1.1% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLDE trades at $25.50, down slightly (-0.12%) on the day, with strong fundamental metrics including a P/E of 6.16 and net income margin of 40.02%. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results scheduled for October 27, 2026. Revenue growth from $1.16B in 2025 to projected $1.4B in 2026 demonstrates solid business momentum, supported by expanded insurance offerings in key markets.
The stock presents attractive value with strong profitability and analyst support (80% buy ratings), though hurricane exposure in Florida remains a key risk. Current price sits near consensus target of $25.00, suggesting limited near-term upside but solid fundamentals for long-term investors. Management's share repurchase program and dividend initiation provide additional shareholder value support.
SNY trades at $39.77, up 0.08% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and announced a significant expansion of its immunology alliance with Regeneron, valued up to $8 billion. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%.
The outlook is mixed; recent collaborations and earnings beats provide growth catalysts, but a projected decline in 2026 net income to $4.0 billion and bearish technical indicators suggest near-term headwinds. Risks include execution of new partnerships and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Slide Insurance Holdings Inc. Common Stock
Slide Insurance Holdings, Inc. is a technology-enabled insurance company based in Florida that underwrites coastal specialty personal lines insurance, including homeowners and condominium unit owner policies, and also provides reinsurance and insurance agency services.
Read more on SLDE →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
